Correct end use during end joining and radioresistance
Correct end use during end joining and radioresistance
批准号:
8765425
负责人:
Jeremy Michael Stark
金额:
$7.33万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-01 至 2017-05-31
关键词:
AffectAnaphaseBindingBiochemicalBiological AssayCell DeathCell NucleusCellsCessation of lifeChromosomal RearrangementChromosomesCollaborationsComplementComplexCytogeneticsDNA DamageDNA Double Strand BreakDNA RepairDNA Sequence RearrangementDNA repair proteinDNA-PKcsDefectDevelopmentDistalEnsureEventExcisionFigs - dietaryFrequenciesGeneticGenomic DNAGoalsHumanIonizing radiationLeadMalignant NeoplasmsMammalian CellMeasuresMediatingMissionMitoticModelingNBS1 geneOutcomePatientsPhosphotransferasesPublic HealthRNA InterferenceRadiation ToxicityRadiation therapyRadioresistanceRadiosensitizationRelative (related person)RelianceReporterResearchResistanceRoleSeriesSiteSystemTestingUnited States National Institutes of HealthWorkbasecancer therapydesignendodeoxyribonuclease SceIhomologous recombinationimprovedinnovationinsightmolecular markermutantneoplastic cellnovelnovel therapeuticsnuclease Irepairedresponsestandard caretherapeutic targettumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ionizing radiation (IR) can cause to significant tumor cell death, however resistance to radiotherapy can limit its efficacy. IR induces DNA double-strand breaks (DSBs) that can lead to toxic chromosomal rearrangements; such that limiting these rearrangements may be critical for radioresistance. Such IR-induced chromosomal rearrangements likely form via end joining (EJ) that uses incorrect DSB ends during repair. Thus, our long-term goal is to define the factors that limit rearrangements during EJ, and thereby develop therapeutic targets for tumor radiosensitization. To advance this goal, we developed a unique assay to quantify the use of correct versus incorrect ends during EJ of multiple DSBs. Using a chromosomal reporter with two tandem DSBs, and our technical innovation of generating site-specific non-cohesive DSBs, we can measure EJ that uses proximal ends that flank a single DSB versus EJ that uses distal ends of two DSBs. Distal end use during EJ is incorrect, since it causes a deletion rearrangement. Using this system, we found that the DNA damage response factors RAD50 and DNA-PKcs are important to limit incorrect end use during EJ. Since these factors also promote radioresistance, we propose to test our central hypothesis that the role of RAD50 and DNA-PKcs in limiting incorrect end use during EJ is critical for cellular radioresistance. A corollary of this hypothesis is that the funcion of these factors in limiting incorrect end use during EJ is a target for radiosensitization. Aim 1:
To determine the importance to radioresistance of RAD50 function in limiting incorrect end use during EJ, as compared to its other roles in DNA repair. For this, we will examine a series of RAD50 mutants for the ability to complement a set of DNA repair functions, and promote radioresistance, in RAD50-deficient human cells. Aim 2: To determine the importance to radioresistance of DNA-PKcs function in limiting incorrect end use during EJ, as compared to its other roles in DNA repair. Using a similar approach as Aim 1, we will examine a series of DNA-PKcs mutants for the ability to complement DNA repair functions, and promote radioresistance, in DNA-PKcs-deficient mammalian cells. Aim 3. To determine how increasing the distance between two tandem DSBs affects incorrect end use during EJ, and the relative requirement of RAD50 and DNA-PKcs for limiting such EJ-mediated deletion rearrangements. These proposed studies are significant, because they will provide novel insight into how RAD50 and DNA-PKcs promote radioresistance, which is critical for their development as therapeutic targets for tumor radiosensitization. Our study is innovative because it will establish a new paradigm for understanding the role of RAD50 and DNA-PKcs in promoting radioresistance, and because we propose in Aim 3 to develop a new reporter system to examine how the distance between DSBs affects end use during EJ. Our proposed study is also innovative because it will provide insight into the importance of incorrect end use during EJ for radiation toxicity, which will lead to new therapeutic strategies for tumor radiosensitization.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10669605
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10415198
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
-
批准号:10296356
-
项目类别:
-
资助金额:$40.26万
-
财政年份:2021
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10650718
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10171810
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
The role of O-GlcNAcylation in DNA damage repair and cancer therapy
-
批准号:10399545
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Jeremy Michael Stark
-
依托单位:
Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
-
批准号:9236171
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2016
-
负责人:Jeremy Michael Stark
-
依托单位:
Regulation of Single Strand Annealing Repair of Mammalian Chromosomal Breaks
-
批准号:9901462
-
项目类别:
-
资助金额:$38.89万
-
财政年份:2016
-
负责人:Jeremy Michael Stark
-
依托单位:
THE MECHANISM OF RECOMBINATION-MEDIATED LOSS OF HETEROZYGOSITY IN HUMAN
-
批准号:7382140
-
项目类别:
-
资助金额:$21.12万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7895013
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7658248
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8676686
-
项目类别:
-
资助金额:$21.05万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8370791
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7279126
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7085607
-
项目类别:
-
资助金额:$22.48万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Mechanistic steps of homologous repair in mammalian cells
-
批准号:7478540
-
项目类别:
-
资助金额:$21.83万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:9066590
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Correct end use during end joining and radioresistance
-
批准号:8507612
-
项目类别:
-
资助金额:$20.39万
-
财政年份:2006
-
负责人:Jeremy Michael Stark
-
依托单位:
Analytical Cytometry Core
-
批准号:10328520
-
项目类别:
-
资助金额:$8.85万
-
财政年份:1997
-
负责人:Jeremy Michael Stark
-
依托单位:
Analytical Cytometry
-
批准号:10628585
-
项目类别:
-
资助金额:$5.62万
-
财政年份:1997
-
负责人:Jeremy Michael Stark
-
依托单位:
国内基金
海外基金
RIF1蛋白在处理超细后期桥(ultrafine anaphase bridge)和保障基因组稳定的作用
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:陈英伟
-
依托单位: